|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-3-15
|
|
pubmed:abstractText |
Interactions between the chemokine receptor CXCR4 and its ligand stromal derived factor-1 regulate hematopoietic stem-cell trafficking. AMD3100 is a CXCR4 antagonist that induces rapid mobilization of CD34+ cells in healthy volunteers. We performed a phase I study assessing the safety and clinical effects of AMD3100 in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1095-102
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15020611-Adult,
pubmed-meshheading:15020611-Aged,
pubmed-meshheading:15020611-Antigens, CD34,
pubmed-meshheading:15020611-Dose-Response Relationship, Drug,
pubmed-meshheading:15020611-Female,
pubmed-meshheading:15020611-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:15020611-Heterocyclic Compounds,
pubmed-meshheading:15020611-Humans,
pubmed-meshheading:15020611-Lymphoma, Non-Hodgkin,
pubmed-meshheading:15020611-Male,
pubmed-meshheading:15020611-Middle Aged,
pubmed-meshheading:15020611-Multiple Myeloma,
pubmed-meshheading:15020611-Receptors, CXCR4,
pubmed-meshheading:15020611-Statistics, Nonparametric
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Washington University School of Medicine, St Louis, MO 63110, USA. sdevine@im.wustl.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
